BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s): BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.

CSE:BIOV - Post by User

BioVaxys Technology Corp. > CEO bought the recent financing at .15 now holds 12,982,333

<< Previous

Bullboard Posts

Next >>

Comment by TheWeakendzon Mar 15, 2022 7:54pm

81 Views

Post# 34516956

RE:CEO bought the recent financing at .15 now holds 12,982,333

wendy321cd wrote: shares. Has bought puublic market shares in the .30s three times

Not everyone is a good investor. Who cares what CEO's do. IMO, it means nada. And that goes for every single stock that exists on this planet. It's just a game. Win/lose. Never bet the farm. We shall see what happens in time. If it was that easy, everybody would play the silly stock market??? The odds of winning are much better than playing the lottery, one would think, lol. Glta. Jmo. Do your DD

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale